BioCentury
ARTICLE | Clinical News

Subcutaneous beloranib: Phase III data

January 25, 2016 8:00 AM UTC

Last December, FDA placed a full clinical hold on trials of beloranib after a patient was diagnosed with bilateral pulmonary emboli and died in the 6-month, open-label extension portion of bestPWS. In...